HomeAI · summaries
Storia in 3 fonti
Sales in weight-loss drug Mounjaro double amid surging market appetite
Eli Lilly’s chief executive David Ricks told investors that it was ‘building for the future’
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
- ·
zerohedge.com
"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand
"At the same time, Lilly is building for the future. With our next-generation weight-loss medicine..."
